Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Skin Diseases, Vascular

ClinicalTrials.gov lists 1,295 trials for Skin Diseases, Vascular or a narrower condition beneath it. Novartis Pharmaceuticals has the most among industry and government lead sponsors, with 58.

MeSH D017445 Skin and Connective Tissue Diseases C17 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 128 Phase 1/2 Phase 1/2 44 Phase 2 Phase 2 239 Phase 2/3 Phase 2/3 28 Phase 3 Phase 3 235 Phase 4 Phase 4 94 Not applicable Not applicable 123 Observational Observational 393 Phase 1 Phase 1 128 Phase 1/2 Phase 1/2 44 Phase 2 Phase 2 239 Phase 2/3 Phase 2/3 28 Phase 3 Phase 3 235 Phase 4 Phase 4 94 Not applicable Not applicable 123 Observational Observational 393

Trials per phase

1 more section with rows

10 of the 1,295 trials are tagged with Skin Diseases, Vascular itself; the rest are tagged with a narrower condition beneath it.

Get the Skin Diseases, Vascular report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Skin Diseases, Vascular trials start? (35)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 2 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 112

1990: 1 trials (Phase 2 1) 1992: 1 trials (Phase 3 1) 1994: 2 trials (Not applicable 1, Phase 2 1) 1995: 6 trials (Observational 2, Phase 3 1, Phase 2/3 1, Phase 2 1, Phase 1 1) 1996: 3 trials (Observational 1, Phase 4 2) 1997: 2 trials (Observational 1, Phase 2 1) 1998: 3 trials (Phase 2/3 1, Phase 1 2) 1999: 4 trials (Phase 3 2, Phase 2 2) 2000: 7 trials (Observational 1, Not applicable 1, Phase 4 1, Phase 3 1, Phase 2/3 1, Phase 2 1, Phase 1/2 1) 2001: 6 trials (Phase 4 2, Phase 3 1, Phase 2 2, Phase 1/2 1) 2002: 11 trials (Observational 1, Not applicable 1, Phase 3 4, Phase 2 4, Phase 1 1) 2003: 15 trials (Observational 1, Not applicable 1, Phase 4 3, Phase 3 2, Phase 2 5, Phase 1/2 1, Phase 1 2) 2004: 16 trials (Observational 2, Not applicable 2, Phase 4 2, Phase 3 5, Phase 2/3 1, Phase 2 2, Phase 1 2) 2005: 25 trials (Observational 5, Not applicable 2, Phase 4 2, Phase 3 8, Phase 2/3 3, Phase 2 3, Phase 1/2 1, Phase 1 1) 2006: 24 trials (Observational 6, Phase 4 2, Phase 3 6, Phase 2/3 2, Phase 2 4, Phase 1/2 1, Phase 1 3) 2007: 22 trials (Observational 3, Phase 4 1, Phase 3 8, Phase 2 7, Phase 1/2 1, Phase 1 2) 2008: 25 trials (Observational 6, Not applicable 3, Phase 4 2, Phase 3 6, Phase 2 5, Phase 1/2 2, Phase 1 1) 2009: 31 trials (Observational 10, Phase 4 3, Phase 3 8, Phase 2 8, Phase 1/2 1, Phase 1 1) 2010: 34 trials (Observational 13, Not applicable 6, Phase 4 2, Phase 3 3, Phase 2/3 3, Phase 2 5, Phase 1/2 2) 2011: 36 trials (Observational 9, Not applicable 4, Phase 4 6, Phase 3 7, Phase 2/3 1, Phase 2 7, Phase 1/2 1, Phase 1 1) 2012: 34 trials (Observational 11, Not applicable 1, Phase 4 1, Phase 3 7, Phase 2/3 2, Phase 2 8, Phase 1/2 2, Phase 1 2) 2013: 39 trials (Observational 10, Not applicable 3, Phase 4 3, Phase 3 8, Phase 2/3 1, Phase 2 10, Phase 1/2 2, Phase 1 2) 2014: 61 trials (Observational 17, Not applicable 5, Phase 4 2, Phase 3 18, Phase 2/3 2, Phase 2 8, Phase 1/2 1, Phase 1 8) 2015: 47 trials (Observational 14, Not applicable 5, Phase 4 7, Phase 3 10, Phase 2 8, Phase 1/2 1, Phase 1 2) 2016: 52 trials (Observational 20, Not applicable 9, Phase 4 3, Phase 3 5, Phase 2/3 1, Phase 2 5, Phase 1/2 2, Phase 1 7) 2017: 44 trials (Observational 13, Not applicable 6, Phase 4 4, Phase 3 9, Phase 2 7, Phase 1 5) 2018: 64 trials (Observational 22, Not applicable 10, Phase 4 4, Phase 3 10, Phase 2/3 2, Phase 2 13, Phase 1/2 1, Phase 1 2) 2019: 66 trials (Observational 18, Not applicable 11, Phase 4 3, Phase 3 11, Phase 2 14, Phase 1/2 1, Phase 1 8) 2020: 71 trials (Observational 30, Not applicable 7, Phase 4 4, Phase 3 10, Phase 2 12, Phase 1 8) 2021: 71 trials (Observational 23, Not applicable 4, Phase 4 3, Phase 3 19, Phase 2/3 2, Phase 2 16, Phase 1/2 1, Phase 1 3) 2022: 71 trials (Observational 24, Not applicable 6, Phase 4 5, Phase 3 15, Phase 2/3 1, Phase 2 12, Phase 1/2 3, Phase 1 5) 2023: 72 trials (Observational 28, Not applicable 4, Phase 4 4, Phase 3 12, Phase 2/3 1, Phase 2 11, Phase 1/2 4, Phase 1 8) 2024: 96 trials (Observational 33, Not applicable 8, Phase 4 9, Phase 3 10, Phase 2 14, Phase 1/2 5, Phase 1 17) 2025: 112 trials (Observational 35, Not applicable 10, Phase 4 9, Phase 3 16, Phase 2 18, Phase 1/2 3, Phase 1 21)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 101
2025 112
2024 96
2023 72
2022 71
2021 71
2020 71
2019 66
2018 64
2017 44

Showing 10 of 35 earlier years.

Start your 14-day trial Email me all 35 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 130 trials starting in 2026 and about 110 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 157 trials still running at the 2026-10-09 snapshot; registered median of 23 months across 713 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Skin Diseases, Vascular trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 128
Phase 1/2 44
Phase 2 239
Phase 2/3 28
Phase 3 235
Phase 4 94
Not applicable 123
Observational 393
Expanded access 11

How many Skin Diseases, Vascular trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 69
Recruiting 207
Enrolling by invitation 14
Active, not recruiting 52
Available 6

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Skin Diseases, Vascular trials? (9)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Novartis Pharmaceuticals 58
Shire 40
National Institute of Allergy and Infectious Diseases (NIAID) 22
Takeda 20
BioCryst Pharmaceuticals 17

Showing 5 of 9 sponsors.

Start your 14-day trial Email me all 9 sponsors as a PDF

Which drugs are being tested for Skin Diseases, Vascular? (8)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
RITUXIMAB 37
Cytoxan 25
Prednisone 24
INFLIXIMAB 19
C1 esterase inhibitor [human] (C1INH-nf) 13

Showing 5 of 8 drugs.

Start your 14-day trial Email me all 8 drugs as a PDF

Interventions as named in the registry (7)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Drug: Omalizumab 40
tocilizumab SC 20
Desloratadin 18
Mepolizumab SC 16
Canakinumab, ACZ885 16

Showing 5 of 7 interventions.

Start your 14-day trial Email me all 7 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Skin Diseases, Vascular trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Infection 259 5
Other 168 1
Cardiovascular 124 1
Pneumonia 87 32
Renal 77 1

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Skin Diseases, Vascular? (11)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Comment on "Sirolimus for the treatment of verrucous venous malformation: A retrospective cohort study": Are we missing the lymphatic malformation component? Journal of the American Academy of Dermatology 2023 Yes
Cutaneous findings of familial cerebral cavernous malformation syndrome due to the common Hispanic mutation. American journal of medical genetics. Part A 2020 Yes
Protocol for a randomized multicenter study for isolated skin vasculitis (ARAMIS) comparing the efficacy of three drugs: azathioprine, colchicine, and dapsone. Trials 2020 Yes
Successful treatment of facial vascular skin diseases with a 577-nm pro-yellow laser. Journal of cosmetic dermatology 2019 Yes
Activated STING in a vascular and pulmonary syndrome. The New England journal of medicine 2014 Yes

Showing 5 of 11 publications.

Start your 14-day trial Email me all 11 publications as a PDF

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Skin vascular disease 79379 Exact Orphanet Rare Disease Ontology (ORDO)
Skin vascular disease 79379 Exact Orphadata Science knowledge files, Product 1

Sub-conditions in MeSH (14)

MeSH descendants one level down with at least one trial, most trials first.

+4 more sub-conditions

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence.

Browse all condition evidence pages